SCHEMBL27212944

SCHEMBL27212944

CC(C)(C)OC(=O)N1C(=O)C2(CCC3(CC2)OCCO3)c2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.42
KDM1A O60341 1/20 0.42
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GAA P10253 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 2/20 0.38
EGLN1 Q9GZT9 1/20 0.36
HDAC1 Q13547 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HSD17B10 Q99714 1/20 0.35
AVPR1A P37288 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21912851 0.91 BCHE (0.50) BCHEKDM1APDE4APDE4BPDE4C
SCHEMBL30681524 0.86 BCHE (0.48) BCHEKDM1APDE4APDE4BPDE4C
SCHEMBL21912451 0.86 BCHE (0.48) BCHEKDM1APDE4APDE4BPDE4C
SCHEMBL29807585 0.85 ANPEP (0.41) KMT2ASMN1; SMN2CASP1HDAC1HDAC8
SCHEMBL27212941 0.85 ANPEP (0.41) KMT2ASMN1; SMN2CASP1HDAC1HDAC8
SCHEMBL30666909 0.84 BCHE (0.38) BCHEKDM1APDE4APDE4BPDE4C
SCHEMBL3237107 0.82 KDM1A (0.49) BCHEKDM1APDE4APDE4BPDE4C
SCHEMBL3237114 0.82 KDM1A (0.49) BCHEKDM1APDE4APDE4BPDE4C
SCHEMBL4775639 0.82 BCHE (0.45) BCHEKDM1APDE4APDE4BPDE4C
SCHEMBL13360856 0.81 KDM1A (0.48) BCHEKDM1APDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150293-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS VERNALIS (R&D) LTD (GB) 2024-05-09 US disclosed
EP-4277892-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS Les Laboratoires Servier (FR) 2023-11-22 EP disclosed
WO-2022152705-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS LES LABORATOIRES SERVIER (FR) 2022-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150293-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BAX, BCL2A1 BCHE 4693/4885KDM1A 4324/4885PDE4A 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.